Error loading player: No playable sources found

  To view this video content in its entirety, click on the "Access Content" button and login to your account.

If you do not have an account, register for free.

Please note that the account you create here is different than your Keystone Symposia account at www.keystonesymposia.org used to register for our multi-day conferences and is uniquely for viewing our virtual content.


Rigor in Science: The Challenge of Reproducibility in Biomedical Research

Free
Standard Price
This product is also available as part of the following products:

Every researcher has a story about a compelling result that didn’t reproduce. Sometimes this is due to technical challenges or the experimental approach. However, there are also biological mechanisms that contribute to irreproducible results, and their importance is increasingly recognized by researchers, drug developers, funding agencies, and the general public.

In this discussion, we consider the issue of data reproducibility in preclinical research through a biological lens, focusing on often-neglected variables such as sex, age, microbiome, and circadian rhythms. The roundtable brings together stakeholders from across the biomedical enterprise to explore practical ways of controlling for these variables to maximize the translational potential of preclinical research. The participants include investigators Michael Holtzman, Dana Philpott, and Jeffrey Haspel, who encounter these variables in their research; Patricia Valdez, representing the NIH Extramural Research Integrity Office; and NPR Science Correspondent Richard Harris, who moderates the discussion and brings a lay perspective.

The goal of the discussion is to explore both the tensions and opportunities for exciting science that irreproducible results create in preclinical research. It also considers economical ways for researchers to address biological drivers of irreproducible results, to comply with new standards set out by funding agencies, and to enhance the potential of their work to lead to novel therapies.

Moderator

Speaker Image for Richard  Harris
Science Correspondent, NPR

Panelists

Speaker Image for Michael  Holtzman
Washington University School of Medicine
Speaker Image for Jeffrey Haspel
Washington University in St. Louis
Speaker Image for Dana Philpott
University of Toronto
Speaker Image for Patricia  Valdez
National Institutes of Health
Speaker Image for Michael  Lauer
National Institutes of Health
Speaker Image for Emilie  Marcus
Cell Press
Speaker Image for Alison Farrell
Nature Medicine

Related Products

Thumbnail for Training Next-Gen Underrepresented (UR) Biomedical Scientists: What Works, What’s Wrong, What’s Right on Target
Training Next-Gen Underrepresented (UR) Biomedical Scientists: What Works, What’s Wrong, What’s Right on Target
In today’s climate of tense identity politics, race and gender issues remain hot topics that we, as a nation, grapple with every day…
Thumbnail for Drug Discovery: Current Trends in Medicinal Chemistry
Drug Discovery: Current Trends in Medicinal Chemistry
DRUG | _DRƏꞬ_ | NOUN: A MEDICINE OR OTHER SUBSTANCE WHICH HAS A PHYSIOLOGICAL EFFECT WHEN INGESTED OR OTHERWISE INTRODUCED INTO THE BODY
Thumbnail for Drug Discovery in Africa
Drug Discovery in Africa
_DRUG DISCOVERY RESEARCH IN AFRICA HAS LAGGED BEHIND THAT CARRIED OUT IN THE MORE DEVELOPED NATIONS OF THE WORLD._ Africa is often described as the “next frontier” in the global economy, yet a crippling disease burden continues to choke economic growth on the continent…
Thumbnail for Neuroinflammation: Causes, Concepts and Consequences
Neuroinflammation: Causes, Concepts and Consequences
Neuroinflammation comprises the interaction of two formidably complex organ systems…
Privacy Policy Update: We value your privacy and want you to understand how your information is being used. To make sure you have current and accurate information about this sites privacy practices please visit the privacy center by clicking here.